73538-17-7

Basic information

• Product Name: 4-[²¹¹At]astato-L-phenylalanine
• Synonyms: 4-[²¹¹At]astato-L-phenylalanine
• CAS NO: 73538-17-7
• Molecular Weight: 375.184
• Mol File: 73538-17-7.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: 4-[²¹¹At]astato-L-phenylalanine(CAS DataBase Reference)
• NIST Chemistry Reference: 4-[²¹¹At]astato-L-phenylalanine(73538-17-7)
• EPA Substance Registry System: 4-[²¹¹At]astato-L-phenylalanine(73538-17-7)

Safety Data

• Hazardous Substances Data: 73538-17-7(Hazardous Substances Data)

Upstream product

• 76410-58-7 p-borono-L-phenylalanine 
• 62561-75-5 (R)-2-amino-3-(4-iodophenyl)propanoic acid 
• 1991-81-7 4-iodo-L-phenylalanine 

Relevant articles and documents

211At and 125I-Labeling of (Hetero)Aryliodonium Ylides: Astatine Wins Again

Despite the growing interest in radioiodine and 211At-labeled radiopharmaceuticals, the search for radiolabeling reactions has been somewhat neglected, resulting in a limited number of available radiosynthetic strategies. Herein we report a comparative study of nucleophilic 125I and 211At-labeling of aryliodonium ylides. Whereas radioiodination efficiency was low, 211At-labeling performed efficiently on a broad scope of precursors. The most activated aryliodonium ylides led rapidly to quantitative reactions at room temperature in acetonitrile. For deactivated precursors, heating up to 90 °C in glyme and addition of 2,2,6,6-tetramethylpiperidine-1-oxyl (TEMPO) as radical scavenger appeared essential to avoid precursor degradation and to achieve high radiochemical yields and molar activity. The approach was applied successfully to the preparation of 4-[211At]astatophenylalanine (4-APA), an amino acid derivative increasingly studied as radiotherapeutic drug for cancers. This validated aryliodonium ylides as a valuable tool for nucleophilic 211At-labeling and will complement the short but now growing list of available astatination reactions.

PRODUCTION METHOD FOR RADIOLABELED ARYL COMPOUND

The invention relates to a method of producing the radiolabeled aryl compound (I) Ar—X, or a salt thereof, wherein X is 211At, 210At, 123I, 124I, 125I, or 131I. The method involves reacting the aryl boronic acid compound (II) Ar—Y, or a salt thereof, wherein Y is a borono group (—B(OH)2) or an ester group thereof, with a radionuclide selected from 211At, 210At, 123I, 124I, 125I and 131I, in the presence of an oxidizing agent selected from an alkali metal iodide, an alkali metal bromide, N-bromosuccinimide, N-chlorosuccinimide and hydrogen peroxide, in water.

THERAPY OF HORMONE DEPENDENT CARCINOMA AND HORMONE-REFRACTORY OR METASTASIZED CARCINOMA DERIVED FROM HORMONE DEPENDENT CARCINOMA

The present invention provides a use of a L-phenylalanine conjugated to an alpha-, beta- or Auger-electron emitting isotope selected from the group consisting of bromine-76, bromine-77, bromine-82, iodine-124, iodine-125, iodine-131 and astatine-211 for t